HAVN Life Sciences Inc.
HAVLF
$0.001
$0.000.00%
OTC PK
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 29.89% | 48.08% | 27.60% | 24.63% | -- |
| Total Depreciation and Amortization | -94.05% | -92.33% | -89.57% | -87.30% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.82% | -28.28% | 5.66% | -7.48% | -- |
| Change in Net Operating Assets | 169.78% | 109.85% | 27.94% | 12.19% | -- |
| Cash from Operations | 76.11% | 66.65% | 47.56% | 22.27% | -- |
| Capital Expenditure | 100.00% | 86.04% | 85.32% | -222.39% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 100.00% | 83.60% | -272.43% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 100.00% | -1,080.75% | -4,994.92% | -- |
| Cash from Investing | 101.26% | 100.50% | 25.12% | -447.14% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 75.00% | 33.33% | -100.00% | -300.00% | -- |
| Issuance of Common Stock | 282.19% | -87.91% | -88.38% | -89.77% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 63.47% | 71.30% | 71.23% | -- |
| Cash from Financing | 342.96% | -87.01% | -90.30% | -91.42% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.59% | -1,962.45% | -314.36% | -212.58% | -- |